Bahia Elkamand
Acute Care · Sugar Land, TXNPI 1346754918
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 958 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 23.3% — the pattern of someone who eats at a lot of different presentations. Among acute care clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 958 payments — averaging $23.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$5K
- Sanofi$4K
- GSK$2K
- Regeneron Healthcare Solutions, Inc.$2K
- Actelion Pharmaceuticals US, Inc.$2K
- Electromed, Inc.$1K
- plus $6K from 33 others
What the payments were for
- Consulting fees$4942%
- Food & beverage$21,96897%
- Education$1231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 128 | $5,258 |
| Sanofi | 87 | $3,894 |
| GSK | 134 | $2,291 |
| Regeneron Healthcare Solutions, Inc. | 96 | $2,103 |
| Actelion Pharmaceuticals US, Inc. | 59 | $1,686 |
| Electromed, Inc. | 104 | $1,165 |
| Boehringer Ingelheim | 41 | $798 |
| Mylan Specialty L.p. | 38 | $636 |
| Amgen | 30 | $555 |
| AbbVie | 18 | $401 |
| Insmed, Inc. | 19 | $400 |
| Baxter Healthcare | 27 | $336 |
| Mallinckrodt Hospital Products Inc. | 17 | $318 |
| Philips North America LLC | 29 | $286 |
| Harmony Biosciences LLC | 13 | $264 |
| Johnson & Johnson | 12 | $235 |
| Merck | 11 | $222 |
| Viatris Specialty LLC | 14 | $212 |
| United Therapeutics Corporation | 10 | $203 |
| Advanced Respiratory, Inc | 18 | $190 |
| Verona Pharma, Inc. | 8 | $169 |
| Lilly USA, LLC | 3 | $139 |
| ANI Pharmaceuticals, Inc. | 7 | $116 |
| Grifols USA, LLC | 4 | $99 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $81 |
| E.r. Squibb & Sons, L.L.C. | 3 | $77 |
| Shionogi Inc | 4 | $67 |
| Inogen, Inc. | 3 | $59 |
| Pfizer | 3 | $54 |
| Pulmonx Corporation | 2 | $41 |
| Paratek Pharmaceuticals, Inc. | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 3 | $39 |
| Mayne Pharma Commercial LLC | 2 | $36 |
| Bayer | 1 | $29 |
| Scpharmaceuticals Inc. | 1 | $21 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Sanofi US Services Inc. | 1 | $18 |
| Phadia US Inc. | 1 | $16 |
| Covis Pharma GmbH | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,585 in reported general payments places this provider in the 95th percentile of 2,323 acute care providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 438 | $339,664 |
| OfevNintedanib Esylate | 24 | $303,321 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 76 | $56,884 |
| Breo ElliptaFluticasone/Vilanterol | 46 | $26,458 |
| Spiriva RespimatTiotropium Bromide | 28 | $23,927 |
| XareltoRivaroxaban | 20 | $20,928 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 34 | $17,814 |
| EliquisApixaban | 22 | $13,560 |
| SymbicortBudesonide/Formoterol Fumarate | 41 | $12,894 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 371 | $10,521 |
| BreynaBudesonide/Formoterol Fumarate | 43 | $7,996 |
| Epinephrine | 33 | $5,522 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 27 | $5,379 |
| Voriconazole | 36 | $5,101 |
| Varenicline Tartrate | 12 | $4,589 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $2,291 | $383,936518 claims |
| Boehringer IngelheimOfev, Spiriva Respimat | $798 | $327,24852 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $5,258 | $69,777117 claims |
| Johnson & JohnsonXarelto | $235 | $20,92820 claims |
| PfizerEliquis | $54 | $13,56022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,323 acute care providers in Texas.
Other acute care in Sugar Land
- Summer WaughSugar Land$15K
- Alexandra TrudeauSugar Land$12K
- Jennifer PilotteDallas$232K
- Christie MorrisonSan Antonio$225K
- Amanda BradleyDallas$85K
- Laura WilsonEl Paso$32K
- Kim HuynhCypress$29K
- Martha LibertyDallas$28K
- Afton DickersonHouston$27K
- Eleanor WeltgeHouston$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.